Leerink Partnrs Issues Positive Outlook for enGene Earnings

enGene Holdings Inc. (NASDAQ:ENGN) – Equities research analysts at Leerink Partnrs increased their FY2026 earnings per share estimates for shares of enGene in a note issued to investors on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now expects that the company will earn ($1.85) per share for the year, up from their prior estimate of ($1.89). The consensus estimate for enGene’s current full-year earnings is ($1.57) per share. Leerink Partnrs also issued estimates for enGene’s FY2027 earnings at ($1.74) EPS and FY2028 earnings at ($0.45) EPS.

enGene (NASDAQ:ENGN) last released its quarterly earnings data on Thursday, December 19th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.06.

Several other research firms also recently weighed in on ENGN. Citizens Jmp raised enGene to a “strong-buy” rating in a research note on Monday, November 18th. Raymond James initiated coverage on enGene in a research report on Wednesday, November 27th. They issued an “outperform” rating and a $23.00 price target for the company. JMP Securities reiterated a “market outperform” rating and issued a $18.00 price objective on shares of enGene in a research report on Monday, December 23rd. Finally, HC Wainwright initiated coverage on shares of enGene in a report on Monday, December 23rd. They set a “buy” rating and a $25.00 target price for the company. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $29.78.

enGene Price Performance

Shares of enGene stock opened at $7.29 on Friday. The company has a 50-day moving average of $7.39 and a two-hundred day moving average of $7.54. enGene has a 12-month low of $4.42 and a 12-month high of $18.40. The company has a quick ratio of 16.87, a current ratio of 16.87 and a debt-to-equity ratio of 0.08.

Institutional Trading of enGene

A number of hedge funds have recently bought and sold shares of ENGN. Wolverine Asset Management LLC purchased a new position in shares of enGene during the 3rd quarter worth $37,000. Point72 Asset Management L.P. increased its stake in enGene by 1,410.3% in the third quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company’s stock valued at $4,376,000 after purchasing an additional 619,100 shares during the last quarter. Finally, Franklin Resources Inc. lifted its position in enGene by 48.7% during the third quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company’s stock worth $7,854,000 after buying an additional 389,918 shares during the period. Institutional investors and hedge funds own 64.16% of the company’s stock.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.